170 related articles for article (PubMed ID: 22372904)
1. Molecular changes in mesothelioma with an impact on prognosis and treatment.
Jean D; Daubriac J; Le Pimpec-Barthes F; Galateau-Salle F; Jaurand MC
Arch Pathol Lab Med; 2012 Mar; 136(3):277-93. PubMed ID: 22372904
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
Goto Y; Shinjo K; Kondo Y; Shen L; Toyota M; Suzuki H; Gao W; An B; Fujii M; Murakami H; Osada H; Taniguchi T; Usami N; Kondo M; Hasegawa Y; Shimokata K; Matsuo K; Hida T; Fujimoto N; Kishimoto T; Issa JP; Sekido Y
Cancer Res; 2009 Dec; 69(23):9073-82. PubMed ID: 19887624
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma.
Kubo T; Toyooka S; Tsukuda K; Sakaguchi M; Fukazawa T; Soh J; Asano H; Ueno T; Muraoka T; Yamamoto H; Nasu Y; Kishimoto T; Pass HI; Matsui H; Huh NH; Miyoshi S
Clin Cancer Res; 2011 Aug; 17(15):4965-74. PubMed ID: 21673066
[TBL] [Abstract][Full Text] [Related]
4. Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up.
Destro A; Ceresoli GL; Baryshnikova E; Garassino I; Zucali PA; De Vincenzo F; Bianchi P; Morenghi E; Testori A; Alloisio M; Santoro A; Roncalli M
Lung Cancer; 2008 Mar; 59(3):369-76. PubMed ID: 17920725
[TBL] [Abstract][Full Text] [Related]
5. Integrin-linked kinase, phosphorylated AKT and the prognosis of malignant pleural mesothelioma.
Watzka SB; Setinek U; Stubenberger EB; Tötsch M; Dekan G; Marcher M; Fleck T; Müller MR
Eur J Cardiothorac Surg; 2011 Feb; 39(2):180-4. PubMed ID: 20580243
[TBL] [Abstract][Full Text] [Related]
6. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma.
Gordon GJ; Mani M; Mukhopadhyay L; Dong L; Edenfield HR; Glickman JN; Yeap BY; Sugarbaker DJ; Bueno R
J Pathol; 2007 Mar; 211(4):447-54. PubMed ID: 17253596
[TBL] [Abstract][Full Text] [Related]
7. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
[TBL] [Abstract][Full Text] [Related]
8. Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma.
Gordon GJ; Mani M; Mukhopadhyay L; Dong L; Yeap BY; Sugarbaker DJ; Bueno R
J Pathol; 2007 Mar; 211(4):439-46. PubMed ID: 17253597
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of malignant pleural mesothelioma.
Jaurand MC; Fleury-Feith J
Respirology; 2005 Jan; 10(1):2-8. PubMed ID: 15691231
[TBL] [Abstract][Full Text] [Related]
10. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
Muraoka T; Soh J; Toyooka S; Aoe K; Fujimoto N; Hashida S; Maki Y; Tanaka N; Shien K; Furukawa M; Yamamoto H; Asano H; Tsukuda K; Kishimoto T; Otsuki T; Miyoshi S
Lung Cancer; 2013 Dec; 82(3):485-90. PubMed ID: 24168922
[TBL] [Abstract][Full Text] [Related]
11. [Asbestos and malignant pleural mesothelioma: molecular, cellular and physiopathological aspects].
Mohr S; Keith G; Rihn B
Bull Cancer; 2005 Nov; 92(11):959-76. PubMed ID: 16316830
[TBL] [Abstract][Full Text] [Related]
12. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma.
Fischer JR; Ohnmacht U; Rieger N; Zemaitis M; Stoffregen C; Kostrzewa M; Buchholz E; Manegold C; Lahm H
Lung Cancer; 2006 Oct; 54(1):109-16. PubMed ID: 16893590
[TBL] [Abstract][Full Text] [Related]
13. Genetics of malignant pleural mesothelioma: molecular markers and biologic targets.
Bueno R; Gordon GJ
Thorac Surg Clin; 2004 Nov; 14(4):461-8. PubMed ID: 15559052
[TBL] [Abstract][Full Text] [Related]
14. Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma.
Scherpereel A;
Respir Med; 2007 Jun; 101(6):1265-76. PubMed ID: 17137779
[TBL] [Abstract][Full Text] [Related]
15. [Epidemiology, molecular biology, diagnostic and therapeutic strategy of malignant pleural mesothelioma in 2007 - an update].
Porret E; Madelaine J; Galateau-Sallé F; Bergot E; Zalcman G
Rev Mal Respir; 2007 Oct; 24(8 Pt 2):6S157-64. PubMed ID: 18235409
[TBL] [Abstract][Full Text] [Related]
16. Neurotensin expression and outcome of malignant pleural mesothelioma.
Alifano M; Loi M; Camilleri-Broet S; Dupouy S; Régnard JF; Forgez P
Biochimie; 2010 Feb; 92(2):164-70. PubMed ID: 19932148
[TBL] [Abstract][Full Text] [Related]
17. Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study.
Cesario A; Catassi A; Festi L; Imperatori A; Pericelli A; Galetta D; Margaritora S; Porziella V; Cardaci V; Granone P; Dominioni L; Russo P
Clin Cancer Res; 2005 Mar; 11(5):2026-37. PubMed ID: 15756029
[TBL] [Abstract][Full Text] [Related]
18. [Current insights in malignant pleural mesothelioma].
Bard M; Debrosse D; Caliandro R; Girard P; Grunenwald D; Ruffié P
Bull Cancer; 2002 Jan; 89(1):67-74. PubMed ID: 11847028
[TBL] [Abstract][Full Text] [Related]
19. Management of malignant pleural mesothelioma.
West SD; Lee YC
Clin Chest Med; 2006 Jun; 27(2):335-54. PubMed ID: 16716822
[TBL] [Abstract][Full Text] [Related]
20. Multidisciplinary treatment of malignant pleural mesothelioma.
Ceresoli GL; Gridelli C; Santoro A
Oncologist; 2007 Jul; 12(7):850-63. PubMed ID: 17673616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
